NCT04192006

Brief Summary

Total knee Arthroplasty (TKA) is a highly effective treatment for knee osteoarthritis. Mid- to long-term follow-up studies have shown good clinical outcomes following TKA; despite these results, there is a high incidence of patient dissatisfaction; 20% of patients reporting dissatisfaction in otherwise uncomplicated procedures. One reason for early dissatisfaction may be the trauma of surgery may lead to localised and systemic inflammatory responses that impair postoperative clinical recovery; this in turn influences long-term functional outcomes. Surgical techniques that limit the insult of surgery and help to restore the patient's native knee anatomy and kinematics may help to improve clinical outcomes, functional recovery, and patient satisfaction. The technical objectives of surgery are to restore limb alignment, preserve the joint line, balance flexion and extension gaps, and maintain the normal Q angle for optimal patella tracking. Compromise to the periarticular soft tissue structures may compromise postoperative clinical and functional recovery, reduce stability, and decrease implant survivorship. In conventional jig-based (CO) TKA, bone cuts are most commonly performed using measured resection or gap balancing. The manual error associated with inadvertent soft tissue release during preparation for implantation or tissue damage from the saw blades is an accepted part of the procedure. The evolution of surgical technology has led to the development of robotic-arm assisted TKA, which uses three dimensional images of the patient's native knee anatomy to guide bone resection and optimise implant positioning. The second-generation RIO Robotic Arm Interactive Orthopaedic system (Mako surgical) uses preoperative computerised tomography scans to build a computer-aided design (CAD) model of the patient's knee joint. The Mako robotic software processes this information to calculate the volume of bone requiring resection and creates a three-dimensional haptic window for the RIO robotic arm to resect. In short, the robotic technology in TKA allows execution of the preoperative surgical plan without undue soft tissue release, inadvertent trauma from power tools, and minimal trauma to bone surfaces. Conceptually, this Mako TKA should have reduced soft tissue trauma and inflammatory response as assessed with inflammatory cytokines compared to CO TKA. The overall aim of this single centre, prospective randomised controlled trial is to determine differences in the inflammatory response between CO TKA and Mako TKA. A comprehensive range of local and systemic biochemical markers, thermal response, and macroscopic soft tissue injury outcomes between the two groups will be recorded and correlated to clinical and functional outcomes over 2-year postoperative. Patients undergoing CO TKA will form the control group and those undergoing Mako TKA will form the investigation group.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
30

participants targeted

Target at below P25 for not_applicable knee-osteoarthritis

Timeline
Completed

Started Nov 2018

Longer than P75 for not_applicable knee-osteoarthritis

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 5, 2018

Completed
1.1 years until next milestone

First Submitted

Initial submission to the registry

December 6, 2019

Completed
4 days until next milestone

First Posted

Study publicly available on registry

December 10, 2019

Completed
2.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2021

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2022

Completed
Last Updated

June 28, 2023

Status Verified

June 1, 2023

Enrollment Period

3.2 years

First QC Date

December 6, 2019

Last Update Submit

June 27, 2023

Conditions

Keywords

biomechanicalinflammationmako robotmakoplastysoft tissue injurytotal knee arthroplastytotal knee replacementthermal

Outcome Measures

Primary Outcomes (1)

  • Serum CRP level

    Serum CRP level

    48 hours post-op

Secondary Outcomes (25)

  • C-reactive Protein (CRP)

    6 hours, 1 day, 2 days, 3 days, 7 days, and 28 days following TKA

  • Interleukin-1 beta (IL1 beta)

    6 hours, 1 day, 2 days, 3 days, 7 days, and 28 days following TKA

  • Interleukin-6 (IL6)

    6 hours, 1 day, 2 days, 3 days, 7 days, and 28 days following TKA

  • Tumour necrosis Factor alpha (TNFalpha),

    6 hours, 1 day, 2 days, 3 days, 7 days, and 28 days following TKA

  • Creatine Kinase (CK)

    6 hours, 1 day, 2 days, 3 days, 7 days, and 28 days following TKA

  • +20 more secondary outcomes

Study Arms (2)

Conventional

ACTIVE COMPARATOR

Jig-based procedure

Device: Total Knee Arthroplasty

Robotic arm-assist

EXPERIMENTAL

Mako robotic-arm assist based procedure

Device: Total Knee Arthroplasty

Interventions

Surgical implantation of prosthetic knee using robotic-arm assist

ConventionalRobotic arm-assist

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patient has symptomatic knee osteoarthritis requiring primary TKA
  • Patient and surgeon are in agreement that TKA is the most appropriate treatment
  • Patient is fit for surgical intervention following review by surgeon and anaesthetist
  • Patient is between 18-80 years of age at time of surgery
  • Gender: male and female
  • Patient must be capable of giving informed consent and agree to comply with the postoperative review program
  • Patient must be a permanent resident in an area accessible to the study site
  • Patient must have sufficient postoperative mobility to attend follow-up clinics and allow for radiographs to be taken

You may not qualify if:

  • Patient is not suitable for routine primary TKA e.g. patient has ligament deficiency that requires a constrained prosthesis
  • Patient has inflammatory arthritis e.g. Rheumatoid arthritis
  • Patient has local or systemic autoimmune disease
  • Past medical history of cancer or chronic illness
  • Patient has symptomatic arthritis of the contralateral knee

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University College London Hospital NHS Foundation Trust

London, NW1 2PG, United Kingdom

Location

MeSH Terms

Conditions

Osteoarthritis, KneeArthritisInflammationSoft Tissue Injuries

Interventions

Arthroplasty, Replacement, Knee

Condition Hierarchy (Ancestors)

OsteoarthritisJoint DiseasesMusculoskeletal DiseasesRheumatic DiseasesPathologic ProcessesPathological Conditions, Signs and SymptomsWounds and Injuries

Intervention Hierarchy (Ancestors)

Arthroplasty, ReplacementArthroplastyOrthopedic ProceduresSurgical Procedures, OperativePlastic Surgery ProceduresProsthesis Implantation

Study Officials

  • Fares S Haddad

    UCL Hospitals NHS Foundation Trust

    STUDY CHAIR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, CARE PROVIDER, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

December 6, 2019

First Posted

December 10, 2019

Study Start

November 5, 2018

Primary Completion

December 31, 2021

Study Completion

March 1, 2022

Last Updated

June 28, 2023

Record last verified: 2023-06

Data Sharing

IPD Sharing
Will not share

No plan

Locations